For the first time in Iranian population, we aimed to compare the serum levels of VEGF in patients with prostate cancer with the levels in patients with BPH as well as healthy people and to determine whether it would be a prognostic marker as well as differentiating factor in such patients. This evidence concerns the gene VEGFA and benign prostatic hyperplasia.